JOIN OUR TEAM
Specialty Excipients for Parenteral Pharmaceuticals is a market research program encompassing the consumption and supply of more than 40 specialty excipients used in parenteral formulations.
Consumers’ mounting health concerns, rapidly growing aging populations, the occurrence of chronic diseases, and the willingness to replace pharmaceutical agents are driving the market for nutraceutical actives in Europe and the United States. The territories are two of the three key regional markets for nutraceutical actives, together accounting for around USD 8 billion; the U.S market is estimated to be higher in value. Other reasons for the market increases include healthy lifestyles focusing on wellness, along with the rising number
The U.S. FDA approved five new branded Rx-to-OTC switches in 2020, including eye drops, an external analgesic, and a lice treatment. In addition, private-label companies such as Perrigo and Mylan gained approval for store brand versions of Voltaren Arthritis Pain Gel, Prevacid 24HR proton pump inhibitor, and Nicorette smoking cessation gum this year. These approvals come after a lull in switch activity during the past two years.
Recently, in Europe and Japan there have been increased Rx-to-OTC switch approvals and an environment fostering switch. The OTC men’s health category is growing in Europe, with the switch approval of Recordati’s Fortacin (lidocaine 7.5mg/prilocaine 2.5 mg) spray for premature ejaculation, via the centralized switch procedure through the European Medicines Agency. This drug marks the fifth medicine approved for switch through this centralized regulatory body, and it is expected to be launched throughout the EU on a nonprescription basis
The overall nutraceuticals market is growing at a higher rate than pharmaceuticals. However, the growth in the nutraceutical market does not entirely translate to excipients market growth for nutraceutical OSDFs. The reason: Excipients are mainly used in the nutraceutical oral solid forms of tablets and capsules and not in forms such as protein powders or
Biopharmaceuticals commonly called “biologics,” include a wide variety of products derived from human, animal, or microbial sources with the help of biotechnology. A surge of bio-APIs and their growing penetration into multiple therapies create an attractive market for pharmaceutical chemical suppliers.
Buzz around the “it” ingredient of 2018 continues into 2019, as negative perception continues to dwindle. Cannabis has taken over the wellness trend in all categories, including food and beverages, supplements, and personal care products. Our upcoming Cannabis Beauty: U.S. Market Analysis and Opportunities report dives deep into the regulatory status and key trends and
Biologics: The global pharmaceutical industry is facing a surge biologics. In recent years, biologic drugs have enjoyed a better approval rating than traditional drugs, as biologic drugs have been found to treat major chronic and complex diseases with higher safety and efficacy. The global production of biologics is expected to grow at a rate of
With the uptake of consumer CBD (cannabidiol) products rising at record growth rates, the need to assure consumers of product safety and transparency is of elevated importance. The purpose of the FDA’s Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds public hearing on May 31, 2019 was to give consumers, academia, manufacturers,
OTC indies, companies that are driving significant growth are either early adopters of a particular health trend such as Suja Life or Health-Ade Kombucha or companies that are breathing new life into iconic brands such as Infirst, Focus Consumer Healthcare, and Foundation Consumer Healthcare. These brands, collectively, generated almost $1.8 billion in manufacturer-level sales in
